Trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome.

Kingshott RN, Vennelle M, Coleman EL, 
Engleman HM, Mackay TW, Douglas NJ

Sleep Center, Respiratory Medicine Unit
 The University of Edinburgh, UK  
 ruth.slate@stonebow.otago.ac.nz
Am J Respir Crit Care Med 2001 Mar;163(4):918-23

ABSTRACT

Some patients with the sleep apnea/hypopnea syndrome (SAHS) remain subjectively and objectively sleepy despite using effective continuous positive airway pressure (CPAP) therapy. The aim of this single center study was to determine the efficacy and safety of the novel wake-promoting medication modafinil in the treatment of CPAP-resistant daytime sleepiness. Thirty sleep apneics receiving effective CPAP therapy (objective use, 6.5 1.1 h/night) received daily single doses of 400 mg modafinil or placebo for 2 wk in a double-blind randomized crossover design. Outcome measures were assessed at baseline and at the end of both 2-wk treatment periods. Treatment periods were separated by a 1-wk washout.  Modafinil had no effect on sleepiness as measured by the Epworth Sleepiness Scale or the Multiple Sleep Latency Test (p > 0.1); however, significant improvements in alertness were found with the Maintenance of Wakefulness Test (modafinil 18.3 3.9 min; placebo, 16.6 5.0 min; p < 0.02). No significant treatment-related improvements in cognitive performance or quality of life were found with modafinil (all p > 0.05). There was a significant reduction in CPAP use on modafinil compared to placebo (6.3 1 h/ night; 6.5 1, p = 0.03). This study suggests that modafinil may improve some aspects of alertness in patients with SAHS who remain sleepy during CPAP therapy, but further studies are required to assess the significance of the reduction in CPAP use

 1.   Modafinil  for sustaining the alertness of helicopter pilots
 2.   Modafinil  augmentation of antidepressant treatment
 3.   Modafinil  the unique properties of a new stimulant 
 4.   Modafinil  children with attention-deficit/hyperactivity disorder
 5.   Modafinil  dosage and safety
 6.   Modafinil  successful treatment of hypersomnia & narcolepsy
 7.   Modafinil  narcolepsy: symptoms and management
 8.   Modafinil  amplification of cortical serotonin release
 9.   Modafinil  treatment of alcoholic organic brain syndrome
10.  Modafinil  effect on melatonin, cortisol, and growth hormone
11.  Modafinil  in obstructive sleep apnea-hypopnea syndrome
12.  Modafinil  vs dextroamphetamine in treatment of adult ADHD
13.  Modafinil  efficacy in narcolepsy
14.  Modafinil  switching from narcolepsy drugs to modafinil
15.  Modafinil  dopaminergic transmission mediates CNS stimulants

| Home | Order |